ABVC on Nasdaq
ABVC BIOPHARMA, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Tempest Therapeutics, Inc., Immuneering Corp or Vyome Holdings, Inc, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development4¢$121.1K
- Selling, general and admin95¢$2.9M
- Income tax1¢$24.2K
Out of $296.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $509.6K | |
| Cost of revenue | $763 | |
| Gross profit | $508.8K | |
| Selling, general and administrative expenses | $2.9M | $2.3M |
| Research and development expenses | $121.1K | $179.3K |
| Stock-based compensation | $4.1M | $2.8M |
| Total operating expenses | $7.2M | $5.2M |
| Loss from operations | -$7.2M | -$4.7M |
| Interest income | $167.1K | $87.4K |
| Interest expense | -$415.9K | -$825.9K |
| Operating sublease income | $134.2K | $48.5K |
| Loss on foreign exchange changes | -$77.5K | -$25.1K |
| Loss on investment in equity securities | -$192.8K | -$339.2K |
| Loss on impairment of equity investment | -$803.0K | |
| Write off unclaimed accrued liabilities | $255.6K | |
| Other (loss) income, net | -$13.6K | $134.4K |
| Total other (expenses) | -$1.2M | -$664.3K |
| Loss before provision for income tax | -$8.4M | -$5.4M |
| Provision for income tax expense (benefit) | $24.2K | -$110.5K |
| Net loss | -$8.4M | -$5.3M |
| Net loss attributable to noncontrolling interests | -$468.4K | -$356.2K |
| Net loss attributed to ABVC and subsidiaries | -$7.9M | -$4.9M |
| Foreign currency translation adjustment | $41.9K | -$70.7K |
| Comprehensive loss | -$7.9M | -$5.0M |
| Basic (in Dollars per share) | -$0.39 | -$0.42 |
| Diluted (in Dollars per share) | -$0.39 | -$0.42 |
| Basic (in Shares) | 20.1M shares | 11.7M shares |
| Diluted (in Shares) | 20.1M shares | 11.7M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $681.5K | $248.4K | |
| Restricted cash | $645.5K | $615.4K | |
| Short-term investments | $64.4K | $64.7K | |
| Prepaid expense and other current assets | $346.6K | $96.2K | |
| Total Current Assets | $2.5M | $2.2M | |
| Property and equipment, net | $12.8M | $511.1K | |
| Operating lease right-of-use assets | $1.9M | $640.4K | |
| Long-term investments | $1.9M | $2.3M | |
| Prepayment for long-term investments | $1.1M | $1.1M | |
| Prepayment for asset acquisition | $691.9K | $691.9K | |
| Other non-current assets | $117.0K | $133.1K | |
| Total Assets | $21.1M | $7.5M | |
| Short-term bank and other loans | $755.5K | $840.3K | |
| Accrued expenses and other current liabilities | $4.2M | $3.5M | |
| Contract liabilities | $12.6K | $81.1K | |
| Operating lease liabilities current | $317.6K | $403.6K | |
| Tax payable | $12.0K | ||
| Convertible notes payable third parties, net | $559.0K | $950.0K | |
| Total Current Liabilities | $6.2M | $6.6M | |
| Tenant security deposit | $21.7K | ||
| Operating lease liability non-current | $1.6M | $236.8K | |
| Total Liabilities | $7.8M | $6.8M | |
| Common stock, $0.001 par value, 100,000,000 authorized, 25,053,193 and 13,868,484 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $25.1K | $13.9K | |
| Stock to be issued | $359.0K | $31.0K | |
| Additional paid-in capital | $96.0M | $78.6M | |
| Accumulated deficit | -$76.9M | -$68.9M | |
| Accumulated other comprehensive income | $487.6K | $445.7K | |
| Treasury stock | -$8.9M | -$8.9M | |
| Total Stockholders equity | $11.1M | $1.2M | |
| Noncontrolling interest | $2.2M | -$502.2K | |
| Total Equity | $13.3M | $724.0K | $1.3M |
| Total Liabilities and Equity | $21.1M | $7.5M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 20.0M shares | 20.0M shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued (in Shares) | 25.1M shares | 13.9M shares | |
| Common stock, shares outstanding (in Shares) | 25.1M shares | 13.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$8.4M | -$5.3M |
| Depreciation | $25.3K | $32.0K |
| Stock-based compensation | $4.1M | $2.8M |
| Inventory write-down | $11.5K | |
| Provision for doubtful accounts | $12.0K | |
| Other non-cash expenses, net | $351.1K | $532.8K |
| Loss on investment in equity securities | $192.8K | $339.2K |
| Loss on impairment of equity investment | $803.0K | |
| Amortization of right-of-use asset | $479.5K | $168.9K |
| Inventory | -$11.5K | |
| Prepaid expenses and other current assets | -$71.7K | $12.9K |
| Due from related parties | -$136.5K | -$294.0K |
| Accrued expenses and other current liabilities | $152.2K | $152.8K |
| Contract liabilities | -$68.5K | $1.6K |
| Tenant security deposit | -$16.9K | |
| Taxes payables | $12.0K | -$112.9K |
| Operating lease liabilities | -$474.5K | -$168.9K |
| Net cash used in operating activities | -$3.0M | -$1.8M |
| Loan to related parties | -$1.4M | |
| Repayment from related parties | $203.0K | |
| Transaction costs for acquiring land | -$5.8K | |
| Net cash used in investing activities | -$1.2M | |
| Proceeds from private placement | $3.3M | |
| Proceeds from exercise of warrants | $991.4K | $947.5K |
| Proceeds from convertible notes payable third parties | $499.0K | $342.1K |
| Repayment of convertible notes payable third parties | -$277.3K | -$327.0K |
| Proceeds from convertible notes payable related parties | $390.0K | |
| Repayment of convertible notes payable related parties | -$150.0K | |
| Repayment of short-term bank loans | -$120.4K | -$29.2K |
| Proceeds from related party payables | $599.6K | |
| Proceeds from issuance of warrants | $394.1K | |
| Repurchase of treasury stocks | -$7.3K | |
| Proceeds from issuance of a promissory note | $30.0K | |
| Proceeds from common stock subscription | $31.0K | |
| Net cash provided by financing activities | $4.6M | $2.0M |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | $20.3K | -$24.6K |
| Net increase in cash and cash equivalents and restricted cash | $463.2K | $147.0K |
| Interest expense paid | $31.5K | $22.5K |
| Income taxes paid | $12.1K | $25.9K |
| Issuance of subsidiarys commons stock to acquire the control of the land | $7.7M | |
| Issuance of common stock and stock warrants in the land acquisition | $4.2M | |
| Increase in ROU asset and lease liabilities due to lease amendment | $1.8M | |
| Conversion of convertible note due from related parties to equity investment | $563.8K | |
| Assuming loan in the land acquisition | $500.0K | |
| Issuance of common stock for conversion of debt | $463.8K | $593.7K |
| Issuance of subsidiarys common stock for consulting services | $383.5K |
Former names
Recent filings
- Sep 29, 2026DEF 14A DEFINITIVE PROXY STATEMENT
- Sep 11, 2026PRER14A REVISED PRELIMINARY PROXY STATEMENT
- Aug 27, 20268-K CURRENT REPORT
- Aug 25, 2026PRER14A REVISED PRELIMINARY PROXY STATEMENT
- Aug 17, 2026424B4 PROSPECTUS SUPPLEMENT
- Aug 17, 2026424B4 PROSPECTUS SUPPLEMENT
- Aug 17, 2026424B4 PROSPECTUS SUPPLEMENT
- Aug 17, 2026424B4 PROSPECTUS SUPPLEMENT
- Aug 12, 20268-K/A CURRENT REPORT
- Aug 12, 202610-Q QUARTERLY REPORT
- Aug 12, 2026PRER14A REVISED PRELIMINARY PROXY STATEMENT
- Aug 4, 20268-K CURRENT REPORT
- Jul 28, 2026PRE 14A PRELIMINARY PROXY STATEMENT
- Jul 2, 20268-K CURRENT REPORT
- May 18, 202610-Q QUARTERLY REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10